perrigo compani plc focus develop
distribut private-label gener brand over-the-counter
prescript drug private-label nutrit product
updat fire cylind well
posit tumultu environ
two day delay financi report report full result
modestli ahead expect issu guidanc gener line investor
expect expect growth segment impress
top-lin growth expect gener unit despit continu high-single-digit
expect price eros headwind environ larg gener found
hard drive top-lin growth think durabl busi model combin
brand privat label over-the-counter alongsid specialti gener make name uniqu
invest larg gener space maintain buy rate share
revenu mm cgie mm consensu mm
within chca revenu mm mm estim consensu
mm chci post mm revenu mm expect consensu
mm rx revenu mm quarter line mm
expect consensu mm
report delay due tax chang tax mw remain book accord
compani recent report delay caus misjudg time requir
handl recent tax law chang us belgium enact
late recal on-going account materi weak
compani incom tax process identifi audit weak
remedi audit
guid within expect guid consolid revenu
bn bn cgie bn consensu bn adjust ep expect
compar cgie consensu
expect rx revenu bn growth year
back-half load driven two launch gener segment expect
strong flu season trend particularli impact perrigo result
factor compani guidanc
eye gener unit like shine star expect
revenu growth gener busi follow contract unit
price trend havent abat busi expect high-single-
digit price eros consist expect new launch flow
drive growth continu expect launch proair respond
fda complet respons letter late compani intend launch
undisclos product manag consid lumpi busi
maintain buy rate pt maintain buy rate price target
share modestli adjust estim follow compani
guid continu see uniqu consumer-gener hybrid capabl
continu single-digit top-lin growth new product launch macro privat
label trend us over-the-counter busi coupl modest growth ou
brand over-the-counter busi new launch geograph ration
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
figur perrigo financi perform cgie consensu
chang estim
follow issuanc initi guidanc public compani
modestli updat revenu ep estim
figur chang revenu ep estim
price target deriv blend dcf wacc termin
growth lead valuat weight around forward
ev/ebitda gener group averag estim lead
valuat weight around
risk rate price target
long-term chca growth depend rx-to-otc shift new categori
usual drive low-single-digit growth consum health america
chca busi though increas privat label uptak off-set somewhat retail
price pressur believ signific sustain growth chca busi
driven addit categori switch prescript over-the-counter condit
littl control brand pharma compani fda
resist move statin topic pain nsaid overact bladder treatment
erectil dysfunct product migrain product asthma inhal ophthalm
allergi dry-ey treatment over-the-counter could see pressur chca segment
despit domin share chca addit competitor start gain
long held domin share private-label over-the-counter market recent
over-the-counter switch seen steadi competit tradit prescript gener
compani seek gain traction over-the-counter retail typic assumpt
share given pl over-the-counter market longer guarante
believ continu increment competit could significantli slow perrigo
consum health intern chci busi may prove drag
take correct action segment follow challeng
belgian busi believ growth could slow segment follow brexit
potenti fx challeng continu restructur busi
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
million usd except per share non-gaaprevenueconsum healthcar healthcar profit oper expensescost ipr oper expensestysabri chang expens expense/ incom sale invest -- -- -- -- -- -- -- -loss extinguish non-oper net incomeincom tax analysisbas per share share figur perrigo dcf model
million usd except per share healthcar healthcar depreci amort exclud chang growth estim period long-term period net debt share outstand compani
